INSM

SEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 6

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,705

F5 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

F6 · price: This is the weighted average sales price representing 1,434 shares sold at prices ranging from $175.72 to $176.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001402051-26-000005 · wk-form4_1767910807.xml · nonDerivative · entry 2

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 318,630

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

SEC source: 0001870278-26-000004 · wk-form4_1767910777.xml · nonDerivative · entry 2

Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,090

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

SEC source: 0001685904-26-000004 · wk-form4_1767910926.xml · nonDerivative · entry 1

Adsett Roger · CIK 0001685904 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,462

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

SEC source: 0001604019-26-000004 · wk-form4_1767910881.xml · nonDerivative · entry 1

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,631

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

SEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · derivative · entry 9

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,570 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

SEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 5

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,139

F5 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

SEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 4

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,754

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: This is the weighted average sales price representing 957 shares sold at prices ranging from $174.97 to $175.12 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 3

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,711

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: This is the weighted average sales price representing 2,830 shares sold at prices ranging from $173.92 to $174.80 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 2

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,541

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: This is the weighted average sales price representing 4,783 shares sold at prices ranging from $172.89 to $173.87 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 1

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,324

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001402051-26-000005 · wk-form4_1767910807.xml · nonDerivative · entry 1

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,987

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

SEC source: 0001870278-26-000004 · wk-form4_1767910777.xml · nonDerivative · entry 1

Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,799

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · derivative · entry 14

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,780

Underlying: Common Stock · 7,945 shares

Expires 2034-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F12 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · derivative · entry 13

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,715

Underlying: Common Stock · 4,358 shares

Expires 2033-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F12 · derivative.exercise_date: The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 11

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,754

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F10 · price: This is the weighted average sales price representing 702 shares sold at prices ranging from $175.54 to $176.12 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 10

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,456

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F9 · price: This is the weighted average sales price representing 655 shares sold at prices ranging from $174.20 to $174.43 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 9

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,111

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F8 · price: This is the weighted average sales price representing 1,820 shares sold at prices ranging from $173.05 to $173.87 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 8

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,931

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 7

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,217

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7 · price: This is the weighted average sales price representing 2,836 shares sold at prices ranging from $170.91 to $171.89 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 6

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,053

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F6 · price: This is the weighted average sales price representing 3,205 shares sold at prices ranging from $169.91 to $170.90 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 5

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,258

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: This is the weighted average sales price representing 2,799 shares sold at prices ranging from $168.88 to $169.69 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 4

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,057

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 3

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001604019-26-000002 · wk-form4_1767733720.xml · derivative · entry 3

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,280

Underlying: Common Stock · 31,280 shares

Expires 2036-01-02

F4 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

SEC source: 0001604019-26-000002 · wk-form4_1767733720.xml · nonDerivative · entry 2

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,148

F3 · shares: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest in full on February 1, 2029.

F2 · price: Each RSU was granted on January 2, 2026 for no consideration.

SEC source: 0001604019-26-000002 · wk-form4_1767733720.xml · nonDerivative · entry 1

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,503

F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F2 · price: Each RSU was granted on January 2, 2026 for no consideration.

SEC source: 0001402051-26-000003 · wk-form4_1767733634.xml · derivative · entry 4

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,400

Underlying: Common Stock · 110,400 shares

Expires 2036-01-02

F3 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

SEC source: 0001402051-26-000003 · wk-form4_1767733634.xml · nonDerivative · entry 1

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,083

F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F2 · price: Each RSU was granted on January 2, 2026 for no consideration.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · derivative · entry 12

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,280

Underlying: Common Stock · 31,280 shares

Expires 2036-01-02

F11 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 2

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,754

F3 · shares: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest in full on February 1, 2029.

F2 · price: Each RSU was granted on January 2, 2026 for no consideration.

SEC source: 0001796960-26-000002 · wk-form4_1767733598.xml · nonDerivative · entry 1

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,109

F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F2 · price: Each RSU was granted on January 2, 2026 for no consideration.

SEC source: 0001685904-26-000002 · wk-form4_1767733553.xml · derivative · entry 2

Adsett Roger · CIK 0001685904 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,280

Underlying: Common Stock · 31,280 shares

Expires 2036-01-02

F4 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

SEC source: 0001685904-26-000002 · wk-form4_1767733553.xml · nonDerivative · entry 1

Adsett Roger · CIK 0001685904 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,891

F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F2 · price: Each RSU was granted on January 2, 2026 for no consideration.

F3 · balance_after: Includes 256 shares acquired through the Company's 2018 Employee Stock Purchase Plan.

SEC source: 0001401017-26-000002 · wk-form4_1767733398.xml · derivative · entry 9

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 87,290 shares

Expires 2029-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F10 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

SEC source: 0001401017-26-000002 · wk-form4_1767733398.xml · derivative · entry 8

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,600

Underlying: Common Stock · 27,600 shares

Expires 2036-01-02

F9 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

SEC source: 0001401017-26-000002 · wk-form4_1767733398.xml · nonDerivative · entry 7

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,754

F3 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F8 · price: This is the weighted average sales price representing 200 shares sold at prices ranging from $177.72 to $177.84 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001401017-26-000002 · wk-form4_1767733398.xml · nonDerivative · entry 6

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,954

F3 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7 · price: This is the weighted average sales price representing 9,125 shares sold at prices ranging from $176.68 to $177.67 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001401017-26-000002 · wk-form4_1767733398.xml · nonDerivative · entry 5

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,079

F3 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F6 · price: This is the weighted average sales price representing 12,832 shares sold at prices ranging from $175.67 to $176.62 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001401017-26-000002 · wk-form4_1767733398.xml · nonDerivative · entry 4

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,911

F3 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: This is the weighted average sales price representing 34,103 shares sold at prices ranging from $174.67 to $175.65 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001401017-26-000002 · wk-form4_1767733398.xml · nonDerivative · entry 3

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,014

F3 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: This is the weighted average sales price representing 31,030 shares sold at prices ranging from $173.67 to $174.66 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001401017-26-000002 · wk-form4_1767733398.xml · nonDerivative · entry 2

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,044

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001401017-26-000002 · wk-form4_1767733398.xml · nonDerivative · entry 1

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,754

F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F2 · price: Each RSU was granted on January 2, 2026 for no consideration.

SEC source: 0001870278-26-000002 · wk-form4_1767733498.xml · derivative · entry 2

Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,600

Underlying: Common Stock · 27,600 shares

Expires 2036-01-02

F3 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

SEC source: 0001870278-26-000002 · wk-form4_1767733498.xml · nonDerivative · entry 1

Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,195

F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F2 · price: Each RSU was granted on January 2, 2026 for no consideration.

SEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · derivative · entry 16

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,627

Underlying: Common Stock · 6,259 shares

Expires 2028-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

SEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · derivative · entry 15

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,160

Underlying: Common Stock · 4,440 shares

Expires 2027-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

SEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 12

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 303,911

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F11 · price: This is the weighted average sales price representing 51 shares sold at prices ranging from $171.09 to $171.35 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 11

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 303,962

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F10 · price: This is the weighted average sales price representing 362 shares sold at prices ranging from $170.02 to $170.91 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 10

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 304,324

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F9 · price: This is the weighted average sales price representing 1,938 shares sold at prices ranging from $169.01 to $170.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.